From $1.02 billion in 2022 to almost $3 billion in 2025, Globus Medical's growth is driven by a combination of cutting-edge musculoskeletal implants, regenerative biologics, and enabling technologies alongside an expanding sales footprint. Integration of recent mergers has broadened market reach but imposes operational complexity. While operating income nearly tripled in the period evidencing margin expansion, net income volatility reflects evolving investment in growth and compliance. Regulatory frameworks and supplier concentration create ongoing risk considerations. Capital management is disciplined with significant share repurchases supported by strong free cash flow generation.